Autoimmunity after Alpha-Interferon Therapy for Malignant Carcinoid Tumors
Publication: Annals of Internal Medicine
Volume 115, Number 3
Submit a Comment
Contributors must reveal any conflict of interest. Comments are moderated. Please see our information for authorsregarding comments on an Annals publication.
Abstract
▪ Objective: To determine the incidence of autoantibodies and autoimmune disease and their influence on therapeutic results during alpha-interferon treatment in patients with malignant midgut carcinoid tumors.
▪ Design: Consecutive sample of patients.
▪ Setting: University hospital.
▪ Patients: One hundred thirty-five patients (70 women, 65 men; median age, 59 years) with biopsyproven tumors, liver metastases, and no autoimmune disease.
▪ Interventions: Leukocyte alpha-interferon (n = 88) or alpha-interferon 2b (n = 47) three times a week.
▪ Main Outcome Measures: Signs and symptoms of autoimmune disease or development of autoantibodies to thyroid antigens, nuclear antigens, or gastric parietal cells. Tumor responses were determined by reduced liver metastases or reduced urinary 5-hydroxyindole acetic acid excretion, or both.
▪ Results: Twenty-five patients (19%) developed the following autoimmune disorders after a median of 9 months of therapy: thyroid disease (n = 18), systemic lupus erythematosus (n = 1), pernicious anemia (n = 4), and vasculitis (n = 2). Antibodies to microsomal thyroid antigen or thyroglobulin were detected in 16 patients before therapy and in another 11 patients during therapy. Antinuclear antibodies were detected in 16 patients before and in another 19 patients during therapy. Clinical thyroid disease developed in more than 60% of patients who had or developed thyroid antibodies but in only 7% of initially autoantibody-negative patients. Autoimmunity did not correlate with objective tumor response.
▪ Conclusion: Patients with malignant carcinoid tumors may develop autoimmune disease during alphainterferon therapy, especially when autoantibodies are present. They should therefore be monitored for autoimmunity, which does not appear, however, to influence tumor responses.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
Isaacs A and Lindenmann J. Virus interference. I. The interferon. Proc Royal Soc B. 1957;147:258-67.
2.
Härfast B, Huddlestone J, Casall P, Merigan T, and Oldstone M. Interferon acts directly on human B lymphocytes to modulate immunoglobulin synthesis. J Immunol. 1981;127:2146-50.
3.
Lindahl P, Leary R, and Gresser I. Enhancement by interferon of the specific cytotoxicity of sensitized lymphocytes. Proc Natl Acad Sci USA. 1972;69:721-5.
4.
Scultz R, Papamatheakis J, and Chirgos M. Interferon: an inducer of macrophage activation by polyanions. Science. 1977;197:674-6.
5.
Gidlund M, Örn A, Wigzell H, Senik A, and Gresser I. Enhanced NK cell activity in mice injected with interferon and interferon inducers. Nature. 1978;273:759-61.
6.
Grandér D, Öberg K, Lundqvist M, Tiensuu JE, Eriksson B, and Einhorn S. Interferon-induced enhancement of 2′,5′-oligoadenylate synthetase in mid-gut carcinoid tumours. Lancet. 1990;2:337-40.
7.
Strander H. Interferon Treatment of Human Neoplasia. In: Klein G, Weinhouse S, eds. Advances in Cancer Research, v. 46. London: Academic Press; 1986.
8.
Öberg K, Funa K, and Alm G. Effects of leucocyte interferon upon clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and the carcinoid syndrome. N Engl J Med. 1983;309:129-33.
9.
Öberg K, Norheim I, and Lind E. Treatment of malignant carcinoid tumours with human leukocyte interferon. Long-term results. Cancer Treat Rep. 1986;70:1297-304.
10.
Öberg K, Alm G, and Magnusson A. Treatment of malignant tumours with recombinant interferon alpha-2b (Introna); development of neutralizing interferon antibodies and possible loss of antitumour activity. J Natl Cancer Inst. 1989;81:531-35.
11.
Pangalis G and Griva E. Recombinant alfa-2b-interferon therapy in untreated, stages A and B chronic lymphocytic leukemia. Cancer. 1988;61:869-72.
12.
Fentiman I, Balkwill F, Thomas B, Rusell M, Todd I, and Bottazzo G. An autoimmune aetiology for hypothyroidism following interferon therapy for breast cancer. Eur J Cancer Clin Oncol. 1988;8:1299-303.
13.
Burman P, Karlsson A, Öberg K, and Alm G. Autoimmune thyroid disease in interferon treated patients. Lancet. 1985;2:100-1.
14.
Burman P, Tötterman H, Öberg K, and Karlsson F. Thyroid autoimmunity in patients on long-term therapy with leucocyte derived lnterferon. J Clin Endocrinol Metabol. 1986;63:1086-90.
15.
Abdi E, Brien W, and Venner P. Auto-immune thrombocytopenia related to interferon therapy. Scand J Haematol. 1986;36:515-9.
16.
Rönnblom L, Öberg K, and Alm G. Possible induction of Systemic Lupus Erythematosus by interferon treatment in a patient with a malignant carcinoid tumour. Int J Med. 1990;227:207-10.
17.
Karlsson-Parra A, Burman P, Hagberg H, Öberg K, Alm G, and Klareskog I. Autoantibodies to epithelial cells in patients on long-term therapy with leucocyte-derived alpha-interferon (IFN-α). Clin Exp Immunol. 1990;81:72-5.
18.
Cantell K and Hirvonen S. Large scale production of human leukocyte interferon containing 108 units per ml. J Gen Virol. 1978;39:541-3.
19.
Tan M, Cohen A, and Fries J. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271-7.
20.
Öberg K, Norheim I, Lundqvist G, and Wide L. Cytotoxic treatment of patients with carcinoid tumors-response to streptozotocin alone or in combination with 5-fluorouracil. Acta Oncol. 1987;26:429-32.
21.
Doniach D, Bottazzo G, and Drexhage H. The autoimmune endocrinopathies. In: Lachmann PJ, Peters DK, eds. Clinical Aspects of Immunology, v.2. Oxford: Blackwell Scientific Publications; 1982:903-37.
22.
Tunbridge W, Evered D, and Hall R. The spectrum of thyroid disease in a community: The Whickham survey. Clin Endocrinol. 1977;7:481-93.
23.
Tunbridge W, Brewis M, and French J. Natural history of autoimmune thyroiditis. Br Med J. 1981;282:258-62.
24.
Lazarus J, Burr M, McGregor A, Weetman A, Ludgate M, Woodhead J, and Hall R. The prevalence and progression of autoimmune thyroid disease in the elderly. Acta Endocrinol (Copenh). 1984;106:199-202.
25.
Hawkins B, Dawkins R, and Burger H. Diagnostic significance of thyroid microsomal antibodies in randomly selected population. Lancet. 1980;2:1057-9.
26.
BjØro T, Gaarder P, Smeland E, and Kornstad L. Thyroid antibodies in blood donors: prevalence and clinical significance. Acta Endocrinol (Copenh). 1984;105:324-9.
27.
Fessel G. Systemic lupus erythematosus in the community. Arch Intern Med. 1974;134:1027-35.
28.
Fairley G. Autoantibodies in Malignant Disease. Br J Haematol. 1972;23(Suppl):231-4.
29.
Nelson D. Autoantibodies in cancer patients. Pathology. 1977;9:155-60.
30.
Hawkins B and Dawkins R. Autoantibodies in an Australian population. II. Association with HLA antigens. J Clin Lab Immunol. 1979;2:217-20.
31.
Conlon K, Urba W, Smith J, Steis R, Longo D, and Clark J. Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy. Cancer. 1990;65:2237-42.
32.
Hooks J, Moutsopoulos H, Geis S, Stahl N, Decker J, and Notkins A. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med. 1979;301:5-8.
33.
Hooks J, Jordan G, Cupps T, Moutsopoulos H, Fauci A, and Notkins A. Multiple interferons in the circulation of patients with systemic lupus erythematosus and vasculitis. Arthritis Rheum. 1982;25:396-400.
34.
Kim T, Kanayama Y, Negoro N, Okamura M, Takeda T, and Inoue T. Serum levels of interferons in patients with systemic lupus erythematosus. Clin Exp Immunol. 1987;70:562-9.
35.
Bankhurst A. Interferons and systemic lupus erythematosus. J Rheumatol. 1987;14(Suppl 13):63-7.
36.
Pak C, McArthur R, Eun H, and Yoon J. Association of cytomegalovirus infection with autoimmune type 1 diabetes. Lancet. 1988;2:1-4.
37.
Vento S and Eddlestone A. Immunological aspects of chronic active hepatitis. Clin Exp Immunol. 1987;68:225-32.
38.
Ciampolillo A, Mirakian R, and Schulz T. Retrovirus-like sequences in Graves' disease: implications for human autoimmunity. Lancet. 1989;1:1096-1100.
39.
Schattner A, Duggan D, Naparstek Y, and Schwartz R. Effects of alpha-interferon on the expression of a lupus idiotype in normal humans. Clin Immunol Immunopathol. 1986;38:327-36.
40.
Revel M and Chebath J. Interferon activated genes. Trends Biol Sci. 1986;11:166-70.
41.
De Vries R and Van Rood J. Immunobiology of HLA class-I and class-II molecules. Introduction. Prog Allergy. 1985;36:1-9.
Information & Authors
Information
Published In
Annals of Internal Medicine
Volume 115 • Number 3 • 1 August 1991
Pages: 178 - 183
History
Published in issue: 1 August 1991
Published online: 1 December 2008
Keywords
Copyright
© 1991 American College of Physicians.
Authors
Metrics & Citations
Metrics
Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. For an editable text file, please select Medlars format which will download as a .txt file. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
Download article citation data for:
Autoimmunity after Alpha-Interferon Therapy for Malignant Carcinoid Tumors. Ann Intern Med.1991;115:178-183. doi:10.7326/0003-4819-115-3-178
Autoimmunity after Alpha-Interferon Therapy for Malignant Carcinoid Tumors. Ann Intern Med.1991;115:178-183. doi:10.7326/0003-4819-115-3-178
View More
Login Options:
Purchase
You will be redirected to acponline.org to sign-in to Annals to complete your purchase.
Access to EPUBs and PDFs for FREE Annals content requires users to be registered and logged in. A subscription is not required. You can create a free account below or from the following link. You will be redirected to acponline.org to create an account that will provide access to Annals. If you are accessing the Free Annals content via your institution's access, registration is not required.
Create your Free Account
You will be redirected to acponline.org to create an account that will provide access to Annals.
Comments
0 Comments